In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
Nucleic acid medicine encompassing antisense oligonucleotides (ASOs) has garnered interest as a potential avenue for next-generation therapeutics. However, their therapeutic application has been constrained by challenges such as instability, off-target effects, delivery issues, and immunogenic respo...
Saved in:
Main Authors: | Toshiki Tsuboi, Keita Hattori, Takuji Ishimoto, Kentaro Imai, Tomohito Doke, Junichiro Hagita, Jumpei Ariyoshi, Kazuhiro Furuhashi, Noritoshi Kato, Yasuhiko Ito, Yukiko Kamiya, Hiroyuki Asanuma, Shoichi Maruyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253124002749 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01) -
Unveiling sequence-agnostic mixed-chemical modification patterns for splice-switching oligonucleotides using the NATURA platform
by: Tommaso Tabaglio, et al.
Published: (2025-03-01) -
Nucleic acid therapeutics: Past, present, and future
by: Sajid Naeem, et al.
Published: (2025-03-01) -
Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01) -
Multispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides
by: Kohshi Kusumoto, et al.
Published: (2025-01-01)